Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.

@article{Rabe2007GlobalSF,
  title={Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.},
  author={Klaus F. Rabe and Suzanne S. Hurd and Antonio Anzueto and Peter John Barnes and Sonia A. Buist and Peter Mark Anthony Calverley and Yoshinosuke Fukuchi and Christine R. Jenkins and Roberto Rodr{\'i}guez-Rois{\'i}n and Chris van Weel and Jan Zieliński},
  journal={American journal of respiratory and critical care medicine},
  year={2007},
  volume={176 6},
  pages={
          532-55
        }
}
Chronic obstructive pulmonary disease (COPD) remains a major public health problem. It is the fourth leading cause of chronic morbidity and mortality in the United States, and is projected to rank fifth in 2020 in burden of disease worldwide, according to a study published by the World Bank/World Health Organization. Yet, COPD remains relatively unknown or ignored by the public as well as public health and government officials. In 1998, in an effort to bring more attention to COPD, its… Expand
Integrated management strategies for chronic obstructive pulmonary disease
TLDR
A case-based approach is used to provide practical information about how integrated care using the chronic care model can be applied to the clinical care of a complex patient with COPD, shifting the management goals for COPD from reactive to proactive and ultimately improving outcomes. Expand
Raising Awareness of COPD: A Call to Action by the Readers of COPD
TLDR
Despite increasing awareness in the medical community of the burden and impact of COPD, messages have not been conveyed to patients at highest risk for the disease—men and women with a history of smoking. Expand
Optimizing economic outcomes in the management of COPD
  • R. D. Dal Negro
  • Medicine
  • International journal of chronic obstructive pulmonary disease
  • 2008
TLDR
The effects of guideline recommendations have been only sporadically investigated in pharmaoeconomic terms, even though symptoms and disability have declined substantially; the corresponding improvement in quality of life, and a significant decrease in both direct and indirect costs have been proved to depend on appropriate rehabilitation and pharmacological long-term treatment of the disease. Expand
Detection and follow-up of chronic obstructive pulmonary disease (COPD) and risk factors in the Southern Cone of Latin America. the pulmonary risk in South America (PRISA) study
TLDR
This population-based prospective cohort study will fill knowledge gaps in the prevalence and incidence of chronic obstructive pulmonary disease, patient characteristics and changes in lung function over time as well as quality of life and health care resource utilization. Expand
Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease.
TLDR
A small effect showing the effectiveness of psychological therapies in improving depressive symptoms when compared to no intervention is shown, and the quality of evidence is assessed using the Cochrane 'Risk of bias' evaluation tool. Expand
Primary Care Perspective on Chronic Obstructive Pulmonary Disease Management
Abstract Chronic obstructive pulmonary disease (COPD), which affects > 24 million adults in the United States, is expected to become the third leading cause of mortality by 2030. Because primary careExpand
COPD: it is time to change!
  • C. Tantucci, L. Pini
  • Medicine
  • International journal of chronic obstructive pulmonary disease
  • 2015
TLDR
Given the relevance of exacerbations in the natural history of COPD, greater effort should be placed on recognition of their prevalent type in frequent exacerbators and to prevent them using more tailored and specific treatment. Expand
Biomarkers in the management of COPD
TLDR
The potential influence of many factors leads to the conclusion that, in the future, the best option would be to monitor levels individually, rather than establishing cut-off points for the general COPD population. Expand
Improving Early-Stage Diagnosis and Management of COPD in Primary Care
TLDR
The evidence to date on pharmacologic treatment using short-acting and long-acting anticholinergics and β2-agonists, and nonpharmacologic interventions, such as smoking cessation, pulmonary rehabilitation, and influenza and pneumococcal vaccination in patients with mild and moderate COPD are discussed. Expand
Improving the Management of Chronic Obstructive Pulmonary Disease
TLDR
Interventions that have been demonstrated to improve clinical and economic outcomes for COPD include improved implementation of guidelines, optimized pharmacologic treatment, and risk‐factor reduction. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 693 REFERENCES
Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force.
TLDR
The guidelines are intended for use by physicians involved in the care of patients with COPD, and their main goals are to inform health professionals and to reverse a widespread nihilistic approach to the management of these patients. Expand
Chronic obstructive pulmonary disease: current burden and future projections
TLDR
A summary measure, disability-adjusted life yrs (DALYs), has been developed to simultaneously measure the amount of disease burden due to premature mortality and the amount due to the nonfatal consequences of disease. Expand
The burden of COPD in The Netherlands: results from the Confronting COPD survey.
TLDR
There was scope for improvement in the understanding of the origin and consequences of this disease among the general public, and the way COPD is managed by healthcare professionals, in order to increase the proportion of patients who are diagnosed with COPD and treated in accordance with management guidelines. Expand
Guideline for the management of chronic obstructive pulmonary disease (COPD): 2004 revision.
TLDR
The South African Guideline for the Management of Chronic Obstructive Pulmonary Disease is revised in the light of new insights into the disease and the value of new treatment approaches and drugs, and independent evaluation of the level of evidence is provided. Expand
Epidemiology and costs of chronic obstructive pulmonary disease
TLDR
COPD is under-diagnosed not only in its early stages, but even when lung function is severely impaired, and the message that COPD is both preventable and treatable has yet to be fully understood by most healthcare providers. Expand
Prevalence of anemia in chronic obstructive pulmonary disease: comparison to other chronic diseases.
TLDR
The high prevalence of anemia in hospitalised COPD patients that were treated mostly for exacerbations gives evidence that anemia is also a comorbidity in COPD and may contribute to exercise limitation and dyspnoea. Expand
Mortality in COPD: role of comorbidities
TLDR
The current paper reviews the role of comorbidities in chronic obstructive pulmonary disease mortality, the putative underlying pathogenic link between chronic obstructives pulmonary disease and comorbrid conditions (i.e. inflammation), and the tools used to predict Chronic obstructivemonary disease mortality. Expand
Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination.
TLDR
The relation of impaired lung function to circulating levels of C-reactive protein and fibrinogen and the relation between lung function and markers of inflammation was assessed, adjusting for potential covariates that may also influence these measures. Expand
Complex chronic comorbidities of COPD
TLDR
The current authors believe that lung function measurement, noninvasive assessment of cardiovascular and metabolic functions, and circulating inflammatory markers (e.g. C-reactive protein) might help to better characterise patients with COPD. Expand
COPD stage and risk of hospitalization for infectious disease.
TLDR
The presence of obstructive lung disease is a significant predictor of IDH caused by respiratory tract infections, but not of hospitalizations due to infections outside the respiratory system. Expand
...
1
2
3
4
5
...